Chronic Spontaneous Urticaria — Xolair Did Not Resolve

Reading time: 10 min
WhatsApp ↗
Medical Encyclopedia · Allergy and Clinical Immunology

Chronic Spontaneous Urticaria — Xolair Did Not Resolve

Clinical Summary and Overview

In the realm of allergic and immune-mediated diseases, the topic Chronic Urticaria It occupies a prominent position due to the frequency with which it impacts the daily well-being of children, adults, and the elderly. This publication was prepared with the purpose of fully elucidating the issue. "Chronic Spontaneous Urticaria — Xolair Did Not Resolve It", offering a structured overview from pathophysiology to diagnostic investigation and the safe prevention of new crises.

✔ Medical content reviewed and validated by the founding clinical staff of the Brazil Without Allergies Project

Dr. Marcello Bossois (CRM-RJ 52.73214-1) · Dr. Patricia Schlinkert (CRM/RJ 5274541-3) — more than 30 years of history in Allergy and Immunology, with units in Rio de Janeiro, São Paulo and Paraná. Last reviewed: November 2026.

Chronic Spontaneous Urticaria — Xolair Did Not Resolve

Chronic Spontaneous Urticaria: What to do when treatment with Xolair does not bring improvements?

Daily coexistence with chronic spontaneous urticaria represents a significant challenge to patients' quality of life. It is common for people to report that, even after months of treatment with the monoclonal antibody Xolair (omalizumab) at a dosage of 150 mg, they continue to experience constant itchy lesions without a single day of relief. This situation generates great frustration and requires a thorough medical reassessment to understand the reasons for the therapeutic failure.

When a highly complex treatment fails to achieve the desired result, the first crucial step is to reassess the diagnosis. Chronic urticaria encompasses different clinical subtypes, and often the condition may not be exclusively a classic case of chronic spontaneous urticaria, or it may be associated with other underlying conditions that perpetuate skin inflammation.

Among the points that should be reassessed by the allergy and immunology specialist are:

  • Review of the diagnostic classification: Differentiate subtypes of chronic urticaria, such as induced forms (physical or cholinergic) or variants associated with more complex autoimmune processes, which may exhibit different responses to immunobiological drugs.
  • Investigation of autoimmune comorbidities: Associated systemic autoimmune conditions can make controlling urticaria more challenging, requiring targeted treatment of the root cause and not just the skin symptoms.
  • Dosage adequacy and follow-up time: The assessment of dosage and clinical response should be individualized within the context of each medical record.

Therefore, when faced with therapies that appear ineffective, the safest course of action is to seek in-depth investigation through differential diagnoses and detailed complementary examinations. This content is strictly educational and informative in nature and does not, under any circumstances, replace consultation, diagnosis, and individualized follow-up with a specialist physician.

Developments in Evidence-Based Medicine: Pharmacology of Immunobiologics and Precision Medicine

In Evidence-Based Medicine, the indication of immunobiological agents (monoclonal antibodies and receptor fusion proteins) It is based on the patient's inflammatory endotyping. Selective blocking of molecular targets — such as the neutralization of free IgE by omalizumab (in severe allergic asthma and chronic spontaneous urticaria refractory to quadrupled-dose H1 antihistamines), the dual inhibition of IL-4 and IL-13 interleukin signaling by dupilumab (In moderate to severe atopic dermatitis, eosinophilic/Th2 asthma, and chronic rhinosinusitis with nasal polyposis), the blockade of the TSLP epithelial alarm by tezepelumab or blocking the IL-5/IL-5R pathway — allows control of the inflammatory cascade at its cellular origin, reducing exacerbations and sparing the patient from the adverse metabolic, endocrine, and cardiovascular effects of prolonged systemic corticosteroid use.

💎 Diamond Plan — Peaceful skin, free from constant itching and sleepless flare-ups. Speak with an Allergy and Immunology specialist via teleconsultation, from anywhere in Brazil. Schedule a teleconsultation →

Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.

Pathophysiology of Urticaria and Angioedema: Safe Diagnosis and Management

Mast Cell Activation, Histamine, and the Bradykinin Pathway

When isolated recurrent angioedema occurs without surrounding pruritic plaques, immunological reasoning must distinguish histaminergic conditions from those mediated by bradykinin—including hereditary or acquired angioedema due to functional or quantitative deficiency of C1-esterase inhibitor (C1-INH) and reactions induced by angiotensin-converting enzyme (ACE) inhibitor antihypertensive drugs. This differentiation is vital because bradykinin-related angioedema does not respond to conventional antihistamines or corticosteroids.

Therapeutic Escalation without Overuse of Corticosteroids

Identifying aggravating cofactors—especially the use of nonsteroidal anti-inflammatory drugs (NSAIDs), acute stress, and physical stimuli—is part of the specialized consultation. Through the allergy test well-indicated and requiring continuous monitoring aimed at stabilizing mast cells and, in patients with atopic respiratory comorbidities, at allergy vaccineComplete control of symptoms is achieved while preserving overall health.

Selective Blockade of Cytokines (IL-4, IL-5, IL-13, TSLP) and Immunoglobulin E

Monoclonal antibodies (immunobiologics) have revolutionized the management of severe allergic and immune-mediated diseases that do not achieve full control with conventional therapies. Unlike systemic corticosteroids and classic immunosuppressants—which broadly depress immunity and generate metabolic toxicity—immunobiologics act as highly precise molecular keys, neutralizing specific targets of the inflammatory cascade: such as circulating free IgE (omalizumab), the IL-4 and IL-13 receptor (dupilumab), the eosinophilic pathway of IL-5 (mepolizumab and benralizumab), or the epithelial alarmin TSLP (tezepelumab).

Diamond Plan: Specialized Allergy Treatment Wherever You Are

SIGNATURE
DIAMOND

Allergy-Free Brazil

THE FUTURE OF TREATMENT

💎

  • Allergy and immunostimulant vaccines included.
  • Easy access (upon request)
  • Nationwide coverage — all of Brazil

brasilsemalergia.online

Living hundreds of miles from an allergist or having to interrupt treatment because of the price of vaccines shouldn't be anyone's fate. With the Diamond PlanBrazil Without Allergies brings the same high standard of care from its clinics to your home, with telemedicine consultations and a more accessible path to immunotherapy. Peaceful skin, free from constant itching and sleep-depriving flare-ups.

Why do patients across Brazil choose the Diamond Plan?

  • Teleconsultation with a specialist In Allergy and Immunology, without queues and without long commutes — ideal for those who live far from large cities.
  • easy access to Immunotherapy (including allergy vaccines and immunostimulants) — indicated for the treatment of allergic rhinitis, asthma, bronchitis, atopic dermatitis, insect/mosquito bite allergy (prurigo strophulus), recurrent candidiasis, and for increasing immunity in selected patients — capable of modifying the natural course of allergic disease, always through consultation and individualized prescription.
  • A more accessible route For those facing the high cost of allergy vaccines, this plan offers support for continuity of treatment.
  • Continuous monitoring based on clinical evolution, with adjustments to treatment throughout the entire therapeutic cycle.
  • National coverage, backed by a consolidated physical network and a founding clinical team with over three decades of experience.

More than 30 years caring for people with allergies.

Founded and run by Dr. Marcello Bossois (CRM-RJ 52.73214-1) and by Dr. Patrícia Schlinkert (CRM/RJ 5274541-3)The Brazil Without Allergies Project adds... more than 30 years of history and more than 450,000 free services, with physical presence at Rio de Janeiro, São Paulo and Paraná, one mobile clinic bus that brings testing and consultations to communities with limited access to specialized care and a platform of telemedicine which connects patients from all states to the same standard of care.

START TODAY

Your expert consultation is just a click away.

I want to join the Diamond Plan.Schedule a teleconsultation

Official telemedicine environment: brasilsemalergia.online

Do you prefer to be served in person?

Our clinical units They conduct consultations, allergy tests, and immunotherapy follow-up with doctors in person:

Schedule your in-person appointment. Or check the mobile bus schedule through the customer service center on WhatsApp. (21) 99954-5632.

The indication for immunotherapy, and for any treatment, depends on an individual medical evaluation. This content is for informational purposes only and does not replace consultation with a specialist.

Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.

Conclusion and Summary of Guidelines

It is concluded that the efficient management of issues related to Chronic Urticaria It relies on the combination of high-quality scientific information, environmental prevention, and therapy tailored to each patient's profile. In the face of persistent or recurring symptoms, seek evaluation with an allergist and immunologist—integrating thorough diagnostic investigation and established treatment options. rhinitis treatment Whenever indicated — ensures clinical safety and long-lasting health protection.

Scientific references and authoritative sources

The guidelines on this page follow the guidelines and literature of leading international Allergy and Immunology institutions. For further information: